Research and Markets: New Report Examines Hot Topics and Key Issues for Prostrate Cancer Treatment

DUBLIN, Ireland, March 24 /PRNewswire/ — Research and Markets (http://www.researchandmarkets.com/reports/c14527) has announced the addition of Stakeholder Insight: Prostate Cancer Treatment in the USA to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH )

Prostate cancer is the most common male malignancy in Western countries. Increasing usage of screening and changes in treatment practice means companies will have to adapt to exploit the market. This Insight details physician opinion of currently available products and disease management practice and what they require in the future.

AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists. Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis Taxotere show much greater efficacy and usage of this combination is already significant.

Topics covered include:

– Quantitative treatment data from 80 physicians from the US

– Qualitative feedback on key findings and future trends in the treatment

of prostate cancer and the management of disease and treatment side

effects

– Coverage of the hot topics affecting current treatment patterns, from

the impact of IMRT on brachytherapy to the increasing use of

bisphosphonates

– A strong future focus on key issues, including the increasing use of

third generation cytotoxics in HRPC

This information will enable readers:

– Identify hot topics and key issues for practicing prostate cancer

specialists the questions they really want answered

– Predict future trends in the treatment of prostate cancer and how to

capitalize on forthcoming changes in treatment practice

– Plan product development to fill prostate cancer market niches as

defined by practicing physicians

For more information visit http://www.researchandmarkets.com/reports/c14527

Laura Wood

Senior Manager

Research and Markets

press@researchandmarkets.com

Fax: +353 1 4100 980

Photo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH

Research and Markets

CONTACT: Laura Wood, Senior Manager, Research and Markets,press@researchandmarkets.com, Fax: +353-1-4100-980

Web site: http://www.researchandmarkets.com/reports/c14527